Protocol Ledger

NCT06247085 · Phase III · RECRUITING

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

Interventional Phase III clinical trial protocol NCT06247085 sponsored by Travere Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-28 Enrollment: 70 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06247085
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06247085
Protocol FieldVerified Registry Value
NCT IdentifierNCT06247085
Consolidated Lead SponsorTravere Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment70 participants (ESTIMATED)
Registered Start Date2023-12-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI